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Abstract Methylphenidate (Ritalin) is an increasingly
used medication in the treatment of attention-deficit
hyperactivity disorder (ADHD). Cardiovascular adverse
effects like vasospasm or myocardial infarction are
described as very rare adverse effects. We present the case
of a 21-year-old man diagnosed with ADHD who recently
started therapy with Ritalin Adult 20 mg for at least
3 days. Afterwards he presented with chest pain, elevated
troponin and creatine kinase, and posterolateral ST ele-
vations. A myocarditis was initially supposed. In the
coronary angiography, signs of coronary artery spasm
could be found. The echocardiography showed mild left
ventricular dysfunction; no acute myocarditis could be
found in the cardiac MRI and myocardial biopsy. The
medication with methylphenidate was stopped, and after
12 days the asymptomatic patient was discharged from
hospital.
Key Points
Methylphenidate contains an existent risk for
cardiovascular adverse effects, especially in patients
with pre-existing cardiovascular diseases.
Pharmacological interactions seem to be very
relevant in the treatment with this medication.
An appropriate pretreatment evaluation and
cardiovascular assessment is recommended before
starting a therapy with methylphenidate.
Introduction
Methylphenidate (Ritalin, Novartis Pharmaceutical
Corp.) is an increasingly used medication in the treatment
of attention-deficit hyperactivity disorder (ADHD). The
dopamine and norepinephrine transporters are inhibited by
methylphenidate, therefore the second messenger levels
rise up in the synaptic cleft (re-uptake inhibition) [1]. The
sympathicotonus becomes more active. Cardiovascular
adverse effects are mentioned in the summary of product
characteristics (SPC): arrhythmia, tachycardia palpitations
(C1/100 to\1/10); chest pain (C1/1000 to\1/100); angina
pectoris (C1/10,000 to\1/1000); cardiac arrest, myocar-
dial infarction (\1/10,000).
Case Presentation
A 21-year-old man presented to an accident and emergency
department on a Sunday morning. Starting the evening
before, he had acute chest pain that persisted till the
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morning. Apart from smoking (1.5 pack-years), no other
cardiovascular risk factors could be detected. Known
comorbidities were bronchial asthma, coeliac disease,
depression and ADHD. ADHD was diagnosed 6 years
before. His current medication was citalopram 10 mg
(Cipramil 10 mg), a selective serotonin reuptake inhibitor
(SSRI), once daily, for about 2 years (noncontinuous) and
methylphenidate 20 mg (Ritalin Adult 20 mg) once daily.
He had just recently started therapy with methylphenidate
(3 days ago). Methylphenidate was started because of
progressive problems regarding attention deficits. There
was no ADHD-specific medication in the past (just beha-
viour therapy) and there was no specific medication for his
bronchial asthma or the coeliac disease. Excepting his new
medication, no other medically relevant events during the
last weeks (infections etc.) were reported. Ritalin Adult
has been labelled for use in adult ADHD patients in Ger-
many since 2014.
In the accident and emergency department, a clinical
examination, an electrocardiogram (ECG) and a blood
sample were performed. The results of the physical
examination were without pathological findings, the vital
signs were normal (blood pressure 117/63 mmHg, heart
rate 53/min, temperature 36.9 C). The ECG showed ST
elevations in II, III, aVF, (0.1 mV) and V4–6 (0.2 mV)
(Fig. 1). The troponin rapid test was positive. Therefore,
the patient was immediately transferred to our accident
and emergency department because of the diagnosed ST
elevation myocardial infarction (STEMI). The ECG
results were confirmed in the blood sample, where highly
elevated troponin and creatine kinase (CK) could be
detected (troponin 990 pg/mL; CK 1068 U/L [CK-MB
Fig. 1 Electrocardiography day
1; ST elevations II, III, aVF,
V4–6; 50 mm/s, 10 mm/mV;
GE MAC 2000
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89 U/L]). At the first contact hospital the patient was
given morphine 2.5 mg, acetylsalicylic acid 500 mg and
heparin 5000 IU, intravenously. Afterwards, the chest
pain decreased rapidly. Before performing the coronary
angiography in our department, 60 mg prasugrel (Efient)
was given orally as a starting dose. Percutaneous coronary
angiography was immediately performed. Apart from
signs of a coronary vasospasm in segment 1 of the right
coronary artery (RCA) (Fig. 2), the coronary arteries were
normal. Regular conditions regarding supply area of
coronary arteries could be detected. An acetylcholine
spasm provocation test was not performed. After the
coronary angiography, the patient was monitored in our
Intermediate Care Unit. In the orienting echocardiogra-
phy, a mildly reduced left ventricular ejection fraction
(EF 49 %) could be seen.
During the next 4 days in the Intermediate Care Unit,
the patient remained stable and asymptomatic. A daily oral
dose of acetylsalicylic acid 100 mg (ASS 100 mg Hexal)
was given. CK elevated to 1800 U/L (CK-MB 98 U/L) on
the second day of observation and then decreased succes-
sively to normal values. Troponin fluctuated around
900 pg/mL for the following 5 days, and then decreased
too. The ECG normalised within the first 48 hours after
onset of chest pain (Fig. 3).
The urine toxicological testing was positive for
tetrahydrocannabinol (THC). The patient admitted that he
consumed cannabis 2 days before his admission to hospi-
tal. THC had been sporadically consumed by the patient in
the past.
Because of the diagnostic results, the initial differential
diagnosis was myocarditis. A myocardial biopsy was per-
formed. The histological analysis of the myocardial tissue
demonstrated no active acute myocarditis. Only a moderate
atrophy of cardiomyocytes indirectly indicated a prolonged
or already past myocardial impairment process and was
therefore compatible to a status after myocarditis. Only a
low viral load (106 viral copies/lg, Erythrovirus genotype
1, 40 mRNA copies) was found. The cardiac MRI showed
no signs of acute myocarditis. The echocardiographic
examination before discharge showed a return to a normal
left ventricular function (EF 66 %).
Consequently, acute myocarditis as the reason for the
patients’ symptoms and our diagnostic findings was not
reasonable. We suggested that the STEMI was induced by
a coronary vasospasm because of methylphenidate, as we
could see in our performed coronary angiography. The
medication with methylphenidate was stopped. In a tele-
phone follow-up 1 week after discharge from hospital, the
patient still had no more symptoms.
Discussion
Methylphenidate is used in the treatment of ADHD as the
first-line therapy. The incidence of prescribing methyl-
phenidate for ADHD has shown a significant increase in
recent years, due to widespread diagnosis of the disorder.
Although relevant cardiovascular events have been seen in
some studies [2], no causal relationship with methylphe-
nidate could be proved. Similarly, there were recently
published case reports [3, 4] in which patients had a
STEMI while they were taking methylphenidate.
Regarding the Naranjo Algorithm—Adverse Drug
Reaction Probability Score, a total score of 4 points was
reached in our case. A total score of 1–4 describes a
‘possible’ adverse drug reaction probability. A total score
of 5–8 indicates a ‘probable’ reaction, and a score of 9–13
a ‘definite’ probability. At least a ‘possible’ adverse event
can be seen in our case.
The adrenergic effect of methylphenidate may have
clinical impact, especially for individual patients with
underlying heart disease. Therefore, it is not surprising that
in many studies, an increase in heart rate and blood pres-
sure was observed [5]. Increased cardiac stress is the result.
Regarding the interaction of methyphendiate and
citalopram, methylphenidate may inhibit the metabolism of
SSRIs, causing elevated SSRI plasma concentrations [6].
Fig. 2 Coronary angiography; coronary vasospasm proximal right
coronary artery
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Higher plasma serotonin levels and therefore an increased
serotonergic activity could influence the onset of coronary
artery spasm [7].
In our case, methylphenidate might be assumed to have
induced a coronary spasm as an early adverse effect, which
caused the STEMI [8]. The reduced left ventricular func-
tion in the acute phase is most likely due to vasospasm-
related hibernating myocardium; thus also explaining the
rapid convalescence within a few days.
In this case, we assume that the young patient had been
through latent myocarditis some time before. This
assumption is based on the results of the myocardial
biopsy. There are some case reports describing a higher
rate of coronary vasospasm due to acute myocarditis.
Acute myocarditis can change coronary vasomotility,
induce endothelial dysfunction and lead to coronary
vasospasm [9, 10]. Because of the past myocarditis, there
might be a higher sensitivity of the coronary arteries
regarding vasoactive substances like methylphenidate.
Nevertheless, the disruption of the coronary autonomic
balance in favour of coronary vasoconstriction might be
influenced by other risk factors such as THC use and
smoking. The use of THC might have been a co-factor
regarding the coronary spasm, but because of the signif-
icant delay of symptom onset, a direct relationship seems
to be implausible. There are some case reports describing
a relationship between cannabis and coronary vasospasm,
but are often related to heavy cannabis smokers [11]. Our
patient denied regular or heavy abuse of THC. The quite
low amount of cigarettes per day ( pack per day over
Fig. 3 Electrocardiography day
2; T-negativity III, aVF, V3–5;
50 mm/s, 10 mm/mV; GE
MAC 1200
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6 years; 1.5 pack-years) seems unremarkable as a main
reason for vasospasm in this case.
Unfortunately, no acetylcholine spasm provocation test
was done during the urgently performed coronary angiog-
raphy. It might have provided evidence for elevated
potential regarding coronary vasospasm in our patient.
However, we would have no proof for a direct relationship
between higher coronary vasospasm potential and the use
of methylphenidate. Other factors might have had an
influence on the results of the acetylcholine provocation
test (e.g., as mentioned, latent myocarditis, THC, SSRI).
There have been a few large retrospective cohort studies
which found no evidence for a significantly higher risk of
cardiovascular adverse effects for methylphenidate
[2, 12, 13]. However, the statistical power was limited in
those studies as the absolute risk of cardiovascular events is
quite low in children and adolescents. Also, the issue of
relevant co-medication was hardly addressed in these
studies. A systematic review conducted in 2014 showed
that adverse effects from methylphenidate for adults with
ADHD were not of serious clinical significance [14]. The
most pronounced adverse reactions noted were a decrease
in appetite, weight loss and mild moodiness. Five studies of
this review reported a rise in blood pressure and three
described a rise in heart rate. These results were judged to
present no cause for concern. Nevertheless, there have been
a few case reports indicating a probability for cardiovas-
cular events while using methylphenidate. Thompson and
Thompson [3] described the case of a 27-year-old man who
suffered a myocardial infarction due to a coronary vasos-
pasm related to the use of methylphenidate complicated by
concomitant use of pseudoephedrine. Ruwald et al. [4]
reported a case of a 20-year-old man who had a STEMI
because of methylphenidate overdose. One of the latest
studies is a nationwide self-controlled case-series study
from South Korea [15]. Regarding myocardial infarction,
no significant risk for all exposed time periods could be
found, but risk was higher in the early risk periods after
start of treatment with methylphenidate (first 2 months).
These findings in a cohort of 1224 patients are in line with
our case.
We conclude that before introducing a methylphenidate-
based medication, patients should undergo cardiac evalua-
tion because of the risk of cardiovascular events. A reason-
able awareness of cardiovascular risk potential of
methylphenidate is necessary for the physicians and their
patients and an appropriate pretreatment evaluation is rec-
ommended [16]. Possible risk factors like cardiovascular
ones or drug abuse (cocaine, THC, etc.) should be excluded.
The probability for inducing cardiac side effects
with methylphenidate might be larger in patients with
existing cardiac comorbidities and/or with a relevant co-
medication (e.g. SSRI). Therefore, the administration of
methylphenidate to patients with cardiovascular history and/
or concomitant medication should be carefully checked.
One week after discharge from hospital, the patient
reported no further complaints after discontinuation of the
methylphenidate medication. Therefore, a correlation
between the sudden onset of the complaint and start of
medication seems likely.
This is one of the first case reports reporting an acute
myocardial infarction because of a coronary artery spasm
in a young man as a possible early adverse effect of
methylphenidate. Even a dosage of 20 mg per day (maxi-
mum daily dose 80 mg) might be sufficient to induce this
event after only a short duration of ingestion. Possible co-
factors like latent myocarditis, concomitant SSRI medica-
tion and effect of THC may also have influenced this event.
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